Document Detail

Flecainide in the intrauterine treatment of fetal supraventricular tachycardia.
MedLine Citation:
PMID:  11876808     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To assess the efficacy of flecainide in the intrauterine treatment of fetal supraventricular tachycardia (SVT) with 1 : 1 atrioventricular conduction. DESIGN: Twenty fetuses (21-35 weeks of gestation) with SVT ranging between 215 and 280 bpm were analyzed retrospectively. Fetuses received flecainide and digoxin as either first, second or third line therapy. Intracardiac blood flow, venous Doppler waveforms and cardiotocograms were evaluated before and after drug induced conversion to sinus rhythm. RESULTS: After initiation of combined flecainide and digoxin therapy, the median time interval until final conversion to sinus rhythm was 5 days (range, 0-14 days). The majority of fetuses (n = 15; 75%) converted to sinus rhythm within 7 days of treatment, whereas the remaining five (25%) showed initial reduction of the heart rate to 160-215 bpm over several days, with restoration of a triphasic venous blood flow pattern before late conversion within 7-14 days after initiation of flecainide treatment. One of these fetuses showed a decrease in fetal heart rate to 160-190 bpm without conversion to sinus rhythm but with resolution of hydrops. All fetuses survived. CONCLUSIONS: Flecainide is safe and highly effective in the intrauterine treatment of hydropic fetuses with supraventricular tachycardia. Conversion into sinus rhythm can be expected 72 h after initiation of therapy but may take up to 14 days. Therefore therapy should be continued beyond 72 h, especially when an initial decrease of fetal heart rate is observed which may represent an early therapeutic response.
M Krapp; A A Baschat; U Gembruch; A Geipel; U Germer
Related Documents :
2235138 - Changes in placental blood flow in the normal human fetus with gestational age.
8456088 - The rate of blood flow through the inverted yolk sac placenta of the anesthetized guine...
3966988 - Fetal umbilical artery flow velocity waveforms and placental resistance: pathological c...
12796898 - Changes in inferior vena cava blood flow velocity and diameter during breathing movemen...
12856858 - Effect of salvia miltiorrhiza bunge on cerebral infarct in ischemia-reperfusion injured...
17377078 - Coagulopathy after cardiopulmonary bypass in jehovah's witness patients: management of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology     Volume:  19     ISSN:  0960-7692     ISO Abbreviation:  Ultrasound Obstet Gynecol     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-05     Completed Date:  2002-04-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9108340     Medline TA:  Ultrasound Obstet Gynecol     Country:  England    
Other Details:
Languages:  eng     Pagination:  158-64     Citation Subset:  IM    
Division of Prenatal Medicine, Department of Obstetrics and Gynecology, University of Lübeck, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Digoxin / administration & dosage
Fetal Diseases / drug therapy*
Flecainide / therapeutic use*
Hydrops Fetalis / complications
Tachycardia, Supraventricular / drug therapy*
Ultrasonography, Doppler
Ultrasonography, Prenatal
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 20830-75-5/Digoxin; 54143-55-4/Flecainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fetal aortic isthmus growth and morphology in late gestation.
Next Document:  Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria.